# MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)

> **NCT00076869** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 55 (actual)

## Conditions studied

- Aspergillosis

## Interventions

- **DRUG:** MK0991, caspofungin acetate
- **DRUG:** Comparator: amphotericin B
- **DRUG:** Comparator: lipid formulation of amphotericin B and/or azole

## Key facts

- **NCT ID:** NCT00076869
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2004-09
- **Final completion:** 2005-08
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2015-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00076869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00076869, "MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00076869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*